Gerresheimer is driving innovation in pharmaceutical glass, primary packaging glass products, technologies and digitized processes.
In the future, highly qualified engineers at the recently opened “Gx Glass Innovation and Technology Center” will develop innovative solutions for the phar- maceutical sector that meet today’s and future demand of the pharma industry. During a customer event with more than 100 par- ticipants the CEO Dietmar Siemssen opened the new innovation cen- ter in Vineland/New Jersey/US.
“We are leading in health and well-being delivery. We are developing first- class glass solutions to meet highest quality requirements. In our new in- novation center we will bundle our glass expertise and all our experts to develop new products and technologies, together with our customers in one place. Among those enhanced value propositions for our customers are Gx Elite Glass, ready-to-fill vials, strengthened glass and much more to come,” said Dietmar Siemssen, CEO of Gerresheimer AG, in his open- ing speech at the new Gx Glass Innovation and Technology Center.
Gerresheimer has made significant investments in its production sites in the Americas over the past few years. In the Gx Glass Innovation and Technology Center, the company will intensify glass innovations as well as optimize all its processes to enable the Gerresheimer plants worldwide to make pharmaceutical glass of the highest quality. The team will work on new products, further digitization, process capabilities, camera inspec- tion systems and much more.
Pooled development capacity
There are clear benefits to pooling development capacity at a single site: 25 experts and engineers specialized in glass technology will work to- gether on innovation in a setting that is conducive to collaboration thanks to an open-plan office, project and meeting rooms, allowing interactive co- working with customers onsite. The innovation center is the first of its kind for Gerresheimer Primary Packaging Glass and was recently built next to the tubular glass converting plant in Vineland. Thereby the innovation cen- ter can develop new products and processes very close to a production site, involving the operational expertise of the engineers at that plant.
Gerresheimer at CPhI Worldwide
Gerresheimer at CPhI WorldwideAs a leading specialist in the packaging and administration of drugs, Gerresheimer has participated in CPhI Worldwide for many years. CPhI stands for Convention of Pharmaceutical Ingredients and has been the most important trade fair for the development and marketing of pharmaceutical ingredients for 30 years. This year the CPhI takes place in Frankfurt. Gerresheimer will be at booth 111B10 in Hall 11.2 in the Innopack area.
About Gerresheimer
Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contrib- utes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With plants in Europe, North America, South Amer- ica and Asia, Gerresheimer generates revenues of around EUR 1.4 bn. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, micro pumps, prefillable syringes, injection vials, am- poules, bottles, and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.
12.10.2019, Gerresheimer AG
此网站新闻材料的版权属于公司或第三方的新闻提供者，其所有权利保留。所有新闻材料对其访问者只能限于其本人使用，并且使用此材料的风险由其使用者独自自行承担。严禁对新闻材料进行再次发布和其它商业利用. 作为商业贸易的用途。如果新闻材料由第三方提供，当应用此新闻材料时，每个使用者都同意遵守，并且受此特定的项目的约束。Glass Global并不代表及认可新闻材料中所包含的内容及新闻中的外部网站的内容的准确性及可靠性。
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.